<p>Icare Home Tonometer: A Review of Characteristics and Clinical Utility</p>

Abstract

The Icare HOME (TA022, Icare Oy, Vanda, Finland) is rebound tonometer recently approved by the US Food and Drug Administration in March 2017 designed for selfmeasurement of intraocular pressure (IOP). IOP remains a major modifiable risk factor for glaucoma progression; however, IOP measurements typically occur through single office measurements on Goldmann applanation tonometry (GAT) and do not always reveal the complete picture of patient's IOP patterns and daily fluctuations, which are important for accurate diagnosis and evaluation. Numerous studies have now compared the efficacy of the Icare HOME to that of GAT. The objective of this article is to review the existing literature surrounding the Icare HOME tonometer and its efficacy as a self-tonometer in comparison to GAT. The available literature has shown promising results in its accuracy of measuring IOP but suggests cautious usage in patients with central corneal thicknesses or IOP ranges that are outside of a certain range. This article will also provide details and example cases for when the Icare HOME may be most clinically useful.

COVID-19 and Use of Teleophthalmology (CUT Group): Trends and Diagnoses

“…Expansion of technology such as home tonometry, home OCT (which have already been developed) and further homebased innovation may allow for increased adoption of virtual visits for glaucoma and retina care, especially for established patients. 5,6 Ophthalmology has previously focused on asynchronous forms of telehealth, such as "store-and-forward" imaging to address workforce shortages, not reduce in-person visits. 7 Our study found that ophthalmologists were not well-equipped to shift care from clinics to patients' homes.…”

How to Measure Intraocular Pressure: An Updated Review of Various Tonometers

“…In comparing the reliability and reproducibility of IOP values with iCare tonometry, air tonometry and GAT, Valero et al reported ICC > 0.85 and low differences with GAT [ 95 ]. Several studies have reported that iCare provides reproducible and reliability measurements when compared to other tonometers, although it appears to slightly underestimate GAT readings [ 88 , 95 , 96 , 97 , 98 , 99 , 100 , 101 ]. The repeatability of iCare has been shown to be excellent, with ICC > 0.9 [ 88 , 99 ].…”

“…IOP readings taken with iCare do not appear to be affected by axial length, refractive error, age and gender [ 87 , 100 ]. GAT and rebound tonometry, however, are influenced by corneal characteristics.…”

“…GAT and rebound tonometry, however, are influenced by corneal characteristics. IOP tends to be overestimated for central corneal thicknesses greater than 520 microns [ 82 , 93 , 96 , 99 , 100 , 101 ]. Rebound tonometry also appears to be affected by corneal curvature, corneal hysteresis and disease [ 96 , 100 , 101 ].…”

“…IOP tends to be overestimated for central corneal thicknesses greater than 520 microns [ 82 , 93 , 96 , 99 , 100 , 101 ]. Rebound tonometry also appears to be affected by corneal curvature, corneal hysteresis and disease [ 96 , 100 , 101 ]. Tonometer measurements tend to be more accurate with iCare for middle levels of IOP, ranging 16–23 mmHg [ 100 ].…”